

Serial No. 10/578,013 ----- 3

**RECEIVED  
CENTRAL FAX CENTER  
FEB 25 2008**

### AMENDMENTS TO THE CLAIMS

Claims 1-6 (canceled).

Claim 7 (currently amended). An isolated peptide consisting of 8 to 50 amino acid residues, and comprising an amino acid sequence or analogous sequence thereof, wherein the amino acid sequence is SEQ ID NO:4 or a functional fragment of SEQ ID NO:4 having a length sufficient to provide a 5-fold or greater reduction in influenza virus infectivity.

Claim 8-26 (canceled).

Claim 27 (new). An isolated peptide consisting of SEQ ID NO:4.

Claim 28 (new). The peptide of claim 7, wherein the peptide consists of a functional fragment of SEQ ID NO:4 having a length sufficient to provide a 5-fold or greater reduction in influenza virus infectivity.

Claim 29 (new) An isolated peptide consisting of 8 to 40 amino acid residues of SEQ ID NO:4.

Claim 30 (new). An influenza virus fusion inhibiting agent comprising:  
a peptide consisting of up to 50 amino acid residues;  
wherein the peptide comprises SEQ ID NO:4.

Claim 31 (new). The influenza virus fusion inhibiting agent of claim 30,  
wherein the peptide consists of SEQ ID NO:4.

Claim 32 (new). An influenza virus fusion inhibiting agent comprising:  
a peptide consisting of 8 to 50 amino acid residues;  
wherein the peptide comprises a functional fragment of SEQ ID NO:4 having a length sufficient to provide a 5-fold or greater reduction in influenza virus infectivity.

Claim 33 (new). The influenza virus fusion inhibiting agent of claim 32,  
wherein the peptide consists of a functional fragment of SEQ ID NO:4 having a length sufficient to provide a 5-fold or greater reduction in influenza virus infectivity.